Trials that use: Cochran-Mantel-Haenszel test
New to this method? Read the tutorial →
89 results
- ACTG A5279Independent statistical analysis of ACTG A5279 (NCT01404312), a randomized phase 3 trial comparing a rifapentine-plus-isoniazid regimen with an isoniazid regimen for tuberculosis prevention in people with HIV.
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- ALEXIndependent statistical analysis of the phase 3 ALEX trial comparing alectinib with crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer, including progression-free survival, CNS progression, overall survival, response, quality-of-life endpoints, and…
- ARCHER 1050Independent statistical analysis of ARCHER 1050, the randomized phase 3 trial of dacomitinib versus gefitinib in first-line advanced NSCLC with EGFR-activating mutations, including PFS, overall survival, response, statistical methodology, and interpretation.
- ARCHESComplete statistical analysis of the ARCHES phase 3 trial of enzalutamide plus androgen deprivation therapy versus placebo plus ADT in metastatic hormone sensitive prostate cancer, including rPFS, overall survival, secondary endpoints, statistical…
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ATLASIndependent statistical analysis of the phase 3 ATLAS trial of long-acting cabotegravir plus long-acting rilpivirine in HIV-1 infected adults, including non-inferiority design, Cochran-Mantel-Haenszel analysis, confidence intervals, and Week 48 results.
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- AURELIAIndependent statistical analysis of AURELIA, the randomized phase 3 trial of bevacizumab added to chemotherapy in patients with platinum-resistant ovarian cancer, including progression-free survival, response, overall survival, quality of life, statistical methodology,…
- AXISIndependent statistical analysis of the phase 3 AXIS trial of axitinib versus sorafenib in metastatic renal cell cancer, including progression-free survival, overall survival, objective response rate, statistical methods, and interpretation.
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- CASSIOPEIAA complete statistical analysis of the phase 3 CASSIOPEIA trial evaluating daratumumab in transplant-eligible participants with previously untreated multiple myeloma, including trial design, primary endpoints, reported statistical analyses, safety, and interpretation.
- CELESTIALIndependent statistical analysis of the phase 3 CELESTIAL trial of cabozantinib versus placebo in hepatocellular carcinoma after prior sorafenib, including overall survival, progression-free survival, objective response, trial design, and statistical methodology.
- CheckMate-026Independent statistical analysis of CheckMate-026, a randomized phase 3 trial of nivolumab versus investigator's choice chemotherapy as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer.
- CheckMate-141Independent statistical analysis of CheckMate-141, the randomized phase 3 trial of nivolumab versus investigator's choice therapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
- CheckMate-459Independent statistical analysis of CheckMate-459, a randomized phase 3 trial comparing nivolumab with sorafenib as first treatment in advanced hepatocellular carcinoma, including overall survival, response, progression-free survival, statistical methods, and interpretation.
- CheckMate-816Independent statistical analysis of CheckMate-816, a randomized phase 3 trial of nivolumab plus platinum-doublet chemotherapy versus chemotherapy alone in early-stage non-small cell lung cancer.
- CheckMate-9ERIndependent statistical analysis of CheckMate-9ER, the phase 3 randomized trial of nivolumab combined with cabozantinib versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
- CLEOPATRAIndependent statistical analysis of CLEOPATRA, the randomized phase 3 trial of pertuzumab plus trastuzumab and docetaxel versus placebo plus trastuzumab and docetaxel in previously untreated HER2-positive metastatic breast cancer.
- CLL14Independent statistical analysis of the CLL14 phase 3 trial comparing obinutuzumab plus venetoclax with obinutuzumab plus chlorambucil in chronic lymphocytic leukemia, including time-to-event and response analyses.
- COMET-1Independent statistical analysis of COMET-1, the randomized phase 3 trial of cabozantinib versus prednisone in men with metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone or MDV3100.
- CONTACT-01Independent statistical analysis of CONTACT-01, a randomized phase 3 trial of atezolizumab plus cabozantinib versus docetaxel in metastatic non-small cell lung cancer previously treated with an anti-PD-L1/PD-1 antibody and platinum-containing chemotherapy.
- CONTACT-03Independent statistical analysis of CONTACT-03, a randomized phase 3 trial of atezolizumab plus cabozantinib versus cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment.
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- CRYSTALIndependent statistical analysis of the CRYSTAL phase 3 trial of cetuximab plus FOLFIRI versus FOLFIRI alone in EGFR-expressing metastatic colorectal cancer, including progression-free survival, overall survival, response, statistical methods, and interpretation.
- DESTINY-Breast02Complete statistical analysis of DESTINY-Breast02, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's/physician's choice in previously treated HER2-positive, unresectable and/or metastatic breast cancer.
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMILIAIndependent statistical analysis of the phase 3 EMILIA trial of trastuzumab emtansine versus lapatinib plus capecitabine in HER2-positive locally advanced or metastatic breast cancer, including time-to-event methods, response analyses, safety, and interpretation.
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENESTndIndependent statistical analysis of ENESTnd (NCT00471497), a randomized phase 3 study comparing nilotinib with imatinib in adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
- EV-301Independent statistical analysis of EV-301, evaluating enfortumab vedotin versus chemotherapy in previously treated locally advanced or metastatic urothelial cancer, including overall survival, progression-free survival, response endpoints, methodology, and interpretation.
- EVOKE-01Independent statistical analysis of EVOKE-01, a randomized phase 3 trial comparing sacituzumab govitecan with docetaxel in participants with advanced or metastatic non-small cell lung cancer, including overall survival, progression-free survival, response, patient-reported…
- FLAMINGOComplete statistical analysis of the FLAMINGO phase 3 trial comparing dolutegravir with darunavir/ritonavir, each combined with dual NRTIs in ART-naive participants with HIV-1 infection.
- FRESCO-2Independent statistical analysis of the phase 3 FRESCO-2 trial of fruquintinib plus best supportive care versus placebo plus best supportive care in metastatic colorectal cancer, including overall survival, progression-free survival, response, statistical…
- GADOLINIndependent statistical analysis of the phase 3 GADOLIN trial of obinutuzumab plus bendamustine versus bendamustine alone in participants with rituximab-refractory, indolent non-Hodgkin's lymphoma.
- GLOWIndependent statistical analysis of the phase 3 GLOW trial of zolbetuximab plus CAPOX versus placebo plus CAPOX in CLDN 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma, including time-to-event methodology, reported efficacy results,…
- GRIPHONIndependent statistical analysis of the GRIPHON phase 3 trial of selexipag in pulmonary arterial hypertension, covering its randomized time-to-event endpoint, secondary analyses, statistical methods, confidence intervals, and interpretation.
- GS-US-292-0104Independent statistical analysis of GS-US-292-0104 (NCT01780506), a randomized phase 3 trial comparing E/C/F/TAF with E/C/F/TDF in antiretroviral treatment-naive adults with HIV-1 infection, including its non-inferiority analysis, risk difference, confidence interval, and Cochran-Mantel-Haenszel…
- GS-US-292-0109Independent statistical analysis of GS-US-292-0109 (NCT01815736), a randomized phase 3 trial evaluating switching from a TDF-containing regimen to E/C/F/TAF in virologically suppressed HIV-1-positive participants.
- HER2CLIMB-02Independent statistical analysis of HER2CLIMB-02, the randomized phase 3 trial of tucatinib with ado-trastuzumab emtansine in advanced or metastatic HER2-positive breast cancer, including time-to-event methodology, reported efficacy estimates, safety, and statistical interpretation.
- ICARIA-MMIndependent statistical analysis of the phase 3 ICARIA-MM trial comparing isatuximab, pomalidomide, and dexamethasone with pomalidomide and dexamethasone in refractory or relapsed and refractory multiple myeloma.
- IMblaze370Independent statistical analysis of IMblaze370, a randomized phase 3 trial comparing cobimetinib plus atezolizumab and atezolizumab monotherapy with regorafenib in metastatic colorectal adenocarcinoma.
- IMpassion130Complete statistical analysis of IMpassion130, a randomized phase 3 trial of atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated metastatic triple-negative breast cancer.
- IMpassion131Independent statistical analysis of IMpassion131, a randomized phase 3 trial of atezolizumab plus paclitaxel versus placebo plus paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer.
- IMpower132Independent statistical analysis of IMpower132, a phase 3 randomized trial of atezolizumab plus platinum-pemetrexed versus platinum-pemetrexed in chemotherapy-naive participants with stage IV non-squamous non-small cell lung cancer.
- JAVELIN Head and Neck 100Independent statistical analysis of JAVELIN Head and Neck 100, a randomized phase 3 trial comparing avelumab plus standard of care chemoradiotherapy with placebo plus standard of care chemoradiotherapy in squamous cell carcinoma…
- KEYNOTE-355Independent statistical analysis of KEYNOTE-355, evaluating pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- KRYSTAL-12Independent statistical analysis of KRYSTAL-12, the phase 3 randomized trial of adagrasib versus docetaxel in patients with advanced non-small cell lung cancer with a KRAS G12C mutation.